🔎 Trials Near Me

Home › Clear-cell metastatic renal cell carcinoma › Minnesota

Pag-aaral pangklinika para sa Clear-cell metastatic renal cell carcinoma sa Minnesota

5 pag-aaral para sa Clear-cell metastatic renal cell carcinoma ang naghahanap ng mga kalahok sa mga site sa Minnesota.

Mga Lungsod sa Minnesota

Opisyal na teksto ng pag-aaral (English)

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Research Site, Rochester
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07011719

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Minnesota Oncology Hematology, P.A., Burnsville
  • Minnesota Oncology Hematology, P.A., Chaska
  • Minnesota Oncology Hematology, P.A., Coon Rapids
  • at 6 pa
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07227415

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  • Mayo Clinic in Rochester, Rochester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 5, 2026 · NCT07510334

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

  • Mayo Clinic in Rochester, Rochester
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT06349642

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • Minnesota Oncology - Burnsville, Burnsville
  • Cambridge Medical Center, Cambridge
  • Mercy Hospital, Coon Rapids
  • at 21 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT04510597

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.